Skip to main content
ALMS
NASDAQ Life Sciences

Foresite Capital Reveals 14.5% Stake in Alumis Following IPO

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$25.3
Mkt Cap
$3.227B
52W Low
$3.76
52W High
$31.35
52W Position info
573% above low
Off High info
19% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ALMS has more than doubled off its 52-week low of $3.76.

Summary

Foresite Capital disclosed a 14.5% stake in Alumis Inc. after the company's IPO, with shares acquired through preferred stock conversions and a $2.52M purchase at $18.00 per share.


Key Events · Ownership and Investor Activity · ALMS

  • Foresite Capital Holds 14.5% Stake

    Following the IPO on August 10, 2026, Foresite entities beneficially own 9,181,328 shares, or 14.5% of the class, in Alumis Inc.

  • IPO Purchase of $2.52M

    Fund VI purchased 140,000 shares at $18.00 per share from underwriters, totaling $2,520,000.

  • Preferred Stock Conversions

    Series A-2 and Series B preferred shares converted to common stock at the IPO, contributing 9,041,328 shares to the total stake.

  • Convertible Note Conversion

    A $3.5M convertible note issued to Fund VI in June 2026 converted into common stock at the IPO price.


Analysis · ALMS · Life Sciences

Following Alumis's August 10 IPO, Foresite Capital entities led by board member James Tananbaum hold 9.18 million shares, representing a 14.5% ownership stake. The position was built through pre-IPO preferred stock conversions and a $2.52 million purchase of 140,000 shares at $18.00 per share. A 180-day lock-up agreement prevents immediate selling, but the disclosure signals a major insider's long-term commitment and clarifies the post-IPO ownership structure.

How filings like this one have moved

In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALMS was trading at $25.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $3.76 to $31.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALMS - Latest Insights

ALMS
Sep 09, 2026, 9:39 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $9.82
Real-time Price: $7.23 info
Change: -$2.59 (-26%) info
Market Cap: $962.5M info
ALMS
Sep 01, 2026, 10:56 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $9.04
Real-time Price: $7.23 info
Change: -$1.81 (-20%) info
Market Cap: $962.5M info
ALMS
Sep 01, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $22.80
Real-time Price: $7.23 info
Change: -$15.57 (-68%) info
Market Cap: $962.5M info
ALMS
Sep 01, 2026, 7:34 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $22.80
Real-time Price: $7.23 info
Change: -$15.57 (-68%) info
Market Cap: $962.5M info
ALMS
Aug 13, 2026, 4:19 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $24.41
Real-time Price: $7.23 info
Change: -$17.18 (-70%) info
Market Cap: $962.5M info